Business
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin
Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is complete Test results support the next development step with Phase 1clinical trial expected to commence in April Provides Summary of Expected ...
About this update from Aspire Biopharma Holdings, Inc.
[{"type":"text","content":"Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is complete","length":117,"tagName":"p"},{"type":"text","content":"Test results support the next development step with Phase 1clinical trial expected to commence in April","length":103,"tagName":"p"},{"type":"text","content":"Provides Summary of Expected 2025 Milestones","length":44,"tagName":"p"},{"type":"text","content":"HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology, announced today that Glatt Air Techniques, Inc., part of Glatt Group, a vertically integrated pharmaceutical services company with FDA- and EU-approved sites operating under cGMP conditions, has undertaken FDA-required testing of the Company's high-dose sublingual aspirin product. Based on the feasibility study, Aspire has begun preparations and expects its next phase of clinical trial to commence in April.","length":682,"tagName":"p"},{"type":"text","content":"Aspire's lead product candidate, high-dose sublingual aspirin, is a granular or powder formulation of a soluble, Ph neutral, fast-acting aspirin designed to address cardiology emergencies and pain management. Aspire believes the benefits of "rapid absorption" aspirin include the potential to quickly stop heart attack and stroke; allow high dose absorption for pain management including fast headache relief, post-surgery, cancer pain management, and general pain relief.","length":486,"tagName":"p"},{"type":"text","content":"The Company's formulation was deemed feasible for further development based on the following testing reports provided by Glatt:","length":131,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Validated Aspire's analytical methods for manufacturing the product under cGMP standards.","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Demonstrated that the aspirin and other ingredients purchased for the testing batch of our high-dose aspirin product meets cGMP and FDA standards for purity.","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"Proved through a compatibility study that the active ingred...